# **SENATE . . . . . . . . . . . . . . . . No. 499**

## The Commonwealth of Massachusetts

PRESENTED BY:

#### Harriette L. Chandler

To the Honorable Senate and House of Representatives of the Commonwealth of Massachusetts in General Court assembled:

The undersigned legislators and/or citizens respectfully petition for the adoption of the accompanying bill:

An Act advancing contraceptive coverage and economic security in our state (ACCESS).

#### PETITION OF:

NAME:	DISTRICT/ADDRESS:	
Harriette L. Chandler	First Worcester	
Patricia A. Haddad	5th Bristol	2/22/2017
Robert M. Koczera	11th Bristol	1/24/2017
Jennifer E. Benson	37th Middlesex	1/24/2017
Sarah K. Peake	4th Barnstable	1/24/2017
Marjorie C. Decker	25th Middlesex	1/25/2017
Jay R. Kaufman	15th Middlesex	1/25/2017
Jason M. Lewis	Fifth Middlesex	1/25/2017
Cory Atkins	14th Middlesex	1/25/2017
Michael J. Barrett	Third Middlesex	1/25/2017
Thomas M. McGee	Third Essex	1/25/2017
Ann-Margaret Ferrante	5th Essex	1/25/2017
Danielle W. Gregoire	4th Middlesex	1/25/2017
William N. Brownsberger	Second Suffolk and Middlesex	1/25/2017
Jack Lewis	7th Middlesex	1/26/2017
John W. Scibak	2nd Hampshire	3/9/2017
Carolyn C. Dykema	8th Middlesex	1/26/2017
John J. Lawn, Jr.	10th Middlesex	1/26/2017

Anne M. Gobi  Morcester, Hampden, Hampshire and Middlesex  Joseph A. Boncore  First Stiffolk and Middlesex  1/27/2017  Ruth B. Balser  12th Middlesex  1/27/2017  Patricia D. Jehlen  Second Middlesex  1/27/2017  Michael D. Brady  Second Plymouth and Bristol  1/27/2017  Milliam M. Straus  10th Bristol  David Paul Linsky  Sth Middlesex  1/30/2017  Menise Provost  27th Middlesex  1/30/2017  Mark C. Montigny  Second Bristol and Plymouth  1/31/2017  Mark C. Mortigny  Second Bristol  Middlesex  1/31/2017  Mark C. Mortigny  Mark C. Mortigny  Mark C. Montigny  Second Bristol  1/31/2017  Mark C. Mortigny  Mark C. Mortigny  Mark C. Mortigny  Mark C. Montigny  Mark C. Montigny  Mark C. Montigny  Mark C. Montigny  Middlesex  1/31/2017  Mark C. Montigny	Barbara A. L'Italien	Second Essex and Middlesex	2/2/2017
Middlesex Joseph A. Boncore First Suffolk and Middlesex J/27/2017 Cynthia Stone Creem First Middlesex and Norfolk J/27/2017 Ruth B. Balser July Middlesex Ju	Mike Connolly	26th Middlesex	1/26/2017
Cynhia Stone Creem  First Middlesex and Norfolk  1/27/2017 Ruth B. Balser  12th Middlesex  1/27/2017 Patricia D. Jehlen  Second Middlesex  1/27/2017 Michael D. Brady  Second Plymouth and Bristol  1/27/2017 William M. Straus  10th Bristol  1/27/2017  Nempeth J. Donnelly  Fourth Middlesex  1/30/2017  Nempeth J. Donnelly  Fourth Middlesex  1/30/2017  Mark C. Montigny  Second Bristol and Plymouth  1/30/2017  Nark C. Montigny  Second Bristol and Plymouth  1/30/2017  Nark C. Montigny  Second Bristol and Plymouth  1/30/2017  Nosé F. Tosado  9th Hampden  1/31/2017  Patrick M. O'Connor  Plymouth and Norfolk  1/31/2017  Ray Khan  11th Middlesex  1/31/2017  Norfolk and Plymouth  1/31/2017  James B. Eldridge  Middlesex and Worcester  1/31/2017  James B. Eldridge  Middlesex and Worcester  1/31/2017  James M. Cantwell  4th Plymouth  2/1/2017  James M. Cantwell  4th Plymouth  2/1/2017  Noria A. Ehrlich  8th Essex  2/1/2017  Seven Ultrino  33rd Middlesex  2/1/2017  Kate Hogan  3rd Middlesex  2/1/2017  Sonia Chang-Diaz  Second Suffolk  2/1/2017  Kenneth I. Gordon  21st Middlesex  2/1/2017  Mary S. Keefe  15th Worcester  2/2/2017  Daniel J. Ryan  2nd Suffolk  2/2/2017  Daniel M. Donahue  16th Worcester  2/2/2017  Daniel M. Donahue  16th Worcester  2/2/2017  Daniel M. Garry  36th Middlesex  2/2/2017  Daniel M. Garry  36th Middlesex  2/2/2017	Anne M. Gobi		1/26/2017
Ruth B. Balser   12th Middlesex   1/27/2017 Patricia D. Jehlen   Second Middlesex   1/27/2017 Michael D. Brady   Second Plymouth and Bristol   1/27/2017 Milliam M. Straus   10th Bristol   1/27/2017 David Paul Linsky   5th Middlesex   1/30/2017 Kenneth J. Donnelly   Fourth Middlesex   1/30/2017 Denise Provost   27th Middlesex   1/30/2017 Mark C. Montigny   Second Bristol and Plymouth   1/30/2017 Sal N. DiDomenico   Middlesex and Suffolk   1/30/2017 Oosé F. Tosado   9th Hampden   1/31/2017 Patrick M. O'Connor   Plymouth and Norfolk   1/31/2017 Nay Khan   11th Middlesex   1/31/2017 John F. Keenan   Norfolk and Plymouth   1/31/2017 John F. Keenan   Norfolk and Plymouth   1/31/2017 James B. Eldridge   Middlesex and Worcester   1/31/2017 Julian Cyr   Cape and Islands   2/1/2017 Julianes M. Cantwell   4th Plymouth   2/1/2017 Steven Ultrino   33rd Middlesex   2/1/2017 Kate Hogan   3rd Middlesex   2/1/2017 Keenneth I. Gordon   21st Middlesex   2/1/2017 Kemeth I. Gordon   21st Middlesex   2/1/2017 Mary S. Keefe   15th Worcester   2/2/2017 Daniel J. Ryan   2nd Suffolk   2/2/2017 Daniel J. Ryan   2nd Suffolk   2/2/2017 Daniel J. Ryan   2nd Suffolk   2/2/2017 Daniel J. Donahue   16th Worcester   2/2/2017 Daniel M. Garry   36th Middlesex   2/2/2017 Daniel M. Garry   36th Middlesex   2/2/2017	Joseph A. Boncore	First Suffolk and Middlesex	1/27/2017
Patricia D. Jehlen Michael D. Brady Second Plymouth and Bristol 1/27/2017 William M. Straus 10th Bristol 1/27/2017 David Paul Linsky 5th Middlesex 1/30/2017 Kenneth J. Donnelly Fourth Middlesex 1/30/2017 Denise Provost 27th Middlesex 1/30/2017 Mark C. Montigny Second Bristol and Plymouth 1/30/2017 Sal N. DiDomenico Middlesex and Suffolk 1/30/2017 Oose F. Tosado 9th Hampden 1/31/2017 Patrick M. O'Connor Plymouth and Norfolk 1/31/2017 John F. Keenan Norfolk and Plymouth 1/31/2017 John F. Keenan Norfolk and Plymouth 1/31/2017 John F. Keenan Norfolk and Plymouth 1/31/2017 John F. Keenan Norfolk and Worcester 1/31/2017 John F. Keenan Norfolk and Morfolk 1/31/2017 John S. Eldridge Middlesex and Worcester 1/31/2017 John S. Cape and Islands 2/1/2017 John S. Cape and Islands 2/1/2017 John S. Cantwell 4th Plymouth 2/1/2017 John S. Erhlich 8th Essex 2/1/2017 Steven Ultrino 33rd Middlesex 2/1/2017 Steven Ultrino 33rd Middlesex 2/1/2017 Sonia Chang-Diaz Second Suffolk 2/1/2017 Kenneth I. Gordon 21st Middlesex 2/1/2017 Sonia Chang-Diaz Second Suffolk 2/1/2017 Sean Garballey 2rd Middlesex 2/1/2017 John B. Lovely Second Essex 2/2/2017 John B. Lovely Second Essex 2/2/2017 John B. Lovely John B. Morias 11th Hampden 2/2/2017 John B. Motias 16th Worcester 2/2/2017 John B. Matias 16th Essex 2/2/2017	Cynthia Stone Creem	First Middlesex and Norfolk	1/27/2017
Michael D. Brady William M. Straus 10th Bristol 1/27/2017 David Paul Linsky 5th Middlesex 1/30/2017 Kenneth J. Donnelly Fourth Middlesex 1/30/2017 Denise Provost 27th Middlesex 1/30/2017 Mark C. Montigny Second Bristol and Plymouth 1/30/2017 Sal N. DiDomenico Middlesex and Suffolk 1/30/2017 José F. Tosado 9th Hampden 1/31/2017 Patrick M. O'Connor Plymouth and Norfolk 1/31/2017 Kay Khan 11th Middlesex 1/31/2017 Paul R. Heroux 2nd Bristol John F. Keenan Norfolk and Plymouth 1/31/2017 James B. Eldridge Middlesex and Worcester 1/31/2017 James B. Eldridge Middlesex and Worcester 1/31/2017 James M. Cantwell 4th Plymouth 2/1/2017 James M. Cantwell 4th Plymouth 2/1/2017 Steven Ultrino 33rd Middlesex 2/1/2017 Steven Ultrino 32rd Middlesex 2/1/2017 Steven Ultrino 32rd Middlesex 2/1/2017 Steven Ultrino 33rd Middlesex 2/1/2017 Steven Ultrino 32rd Middlesex 3/2/2017 Steven Ultrino 33rd Middlesex 3/2/2017	Ruth B. Balser	12th Middlesex	1/27/2017
William M. Straus David Paul Linsky Sth Middlesex 1/30/2017 Kenneth J. Donnelly Fourth Middlesex 1/30/2017 Denise Provost 27th Middlesex 1/30/2017 Mark C. Montigny Second Bristol and Plymouth 1/30/2017 Sal N. DiDomenico Middlesex and Suffolk 1/30/2017 Oosé F. Tosado 9th Hampden 1/31/2017 Patrick M. O'Connor Plymouth and Norfolk 1/31/2017 Kay Khan 11th Middlesex 1/31/2017 John F. Keenan Norfolk and Plymouth 1/31/2017 John F. Keenan Norfolk and Plymouth 1/31/2017 John F. Keenan Norfolk and Plymouth 1/31/2017 James B. Eldridge Middlesex and Worcester 1/31/2017 James B. Eldridge Middlesex and Worcester 1/31/2017 James M. Cantwell 4th Plymouth 2/1/2017 James M. Cantwell 4th Plymouth 2/1/2017 Steven Ultrino 33rd Middlesex 2/1/2017 Steven Ultrino 33rd Middlesex 2/1/2017 Sonia Chang-Diaz Second Suffolk 2/1/2017 Kenneth I. Gordon 21st Middlesex 2/1/2017 Mary S. Keefe 15th Worcester 1/31/2017 Joan B. Lovely Second Essex 2/2/2017 Joan B. Lovely Second Essex 2/2/2017 James J. O'Day 14th Worcester 2/2/2017 Joanes J. O'Day 14th Worcester 2/2/2017 Joan B. Matias 16th Essex 2/2/2017 Joana B. Matias 16th Essex 2/2/2017	Patricia D. Jehlen	Second Middlesex	1/27/2017
David Paul Linsky  Kenneth J. Donnelly  Fourth Middlesex  1/30/2017  Denise Provost  27th Middlesex  1/30/2017  Mark C. Montigny  Second Bristol and Plymouth  1/30/2017  Sal N. DiDomenico  Middlesex and Suffolk  1/31/2017  Patrick M. O'Connor  Plymouth and Norfolk  1/31/2017  John F. Keenan  Norfolk and Plymouth  1/31/2017  James B. Eldridge  Middlesex and Worcester  1/31/2017  James M. Cantwell  Atherous  Second Bristol  Atherous  2/1/2017  James M. Cantwell  Atherous  Second Bristol  Atherous  2/1/2017  Second Bristol  1/31/2017  John F. Keenan  Norfolk and Plymouth  1/31/2017  John G. Cape and Islands  2/1/2017  John J. Flanagan  Worcester and Middlesex  2/1/2017  John S. Keenen Ultrino  33rd Middlesex  2/1/2017  Steven Ultrino  33rd Middlesex  2/1/2017  Second Suffolk  2/1/2017  Second Suffolk  2/1/2017  Second Suffolk  2/1/2017  John J. Ryan  2nd Suffolk  2/2/2017  Daniel J. Ryan  2nd Suffolk  2/2/2017  John B. Lovely  Second Essex  2/2/2017  John B. Lovely  Second Essex  2/2/2017  John B. Lovely  Second Essex  2/2/2017  John B. Lovely  John B. Lovely  Second Essex  2/2/2017  John B. Lovely  J	Michael D. Brady	Second Plymouth and Bristol	1/27/2017
Kenneth J. DonnellyFourth Middlesex1/30/2017Denise Provost27th Middlesex1/30/2017Mark C. MontignySecond Bristol and Plymouth1/30/2017Sal N. DiDomenicoMiddlesex and Suffolk1/30/2017José F. Tosado9th Hampden1/31/2017Patrick M. O'ConnorPlymouth and Norfolk1/31/2017Kay Khan11th Middlesex1/31/2017John F. KeenanNorfolk and Plymouth1/31/2017Paul R. Heroux2nd Bristol1/31/2017James B. EldridgeMiddlesex and Worcester1/31/2017Julian CyrCape and Islands2/1/2017Jennifer L. FlanaganWorcester and Middlesex2/1/2017Johnes M. Cantwell4th Plymouth2/1/2017Lori A. Ehrlich8th Essex2/1/2017Kate Hogan3rd Middlesex2/1/2017Kate Hogan3rd Middlesex2/1/2017Kate Hogan3rd Middlesex2/1/2017Kenneth I. Gordon21st Middlesex2/1/2017Mary S. Keefe15th Worcester2/2/2017Daniel J. Ryan2nd Suffolk2/2/2017Sean Garballey23rd Middlesex2/2/2017Joan B. LovelySecond Essex2/2/2017Daniel M. Donahue16th Worcester2/2/2017Bud Williams11th Hampden2/2/2017James J. O'Day14th Worcester2/2/2017Colleen M. Garry36th Middlesex2/2/2017Huana B. Matias16th Essex2/2/2017	William M. Straus	10th Bristol	1/27/2017
Denise Provost 27th Middlesex 1/30/2017 Mark C. Montigny Second Bristol and Plymouth 1/30/2017 Sal N. DiDomenico Middlesex and Suffolk 1/30/2017 José F. Tosado 9th Hampden 1/31/2017 Patrick M. O'Connor Plymouth and Norfolk 1/31/2017 Kay Khan 11th Middlesex 1/31/2017 John F. Keenan Norfolk and Plymouth 1/31/2017 Paul R. Heroux 2nd Bristol 1/31/2017 James B. Eldridge Middlesex and Worcester 1/31/2017 Julian Cyr Cape and Islands 2/1/2017 Julian Cyr Cape and Islands 2/1/2017 Jumes M. Cantwell 4th Plymouth 2/1/2017 Jumes M. Cantwell 4th Plymouth 2/1/2017 Steven Ultrino 33rd Middlesex 2/1/2017 Steven Ultrino 33rd Middlesex 2/1/2017 Kate Hogan 3rd Middlesex 2/1/2017 Kenneth I. Gordon 21st Middlesex 2/1/2017 Kenneth I. Gordon 21st Middlesex 2/1/2017 Mary S. Keefe 15th Worcester 2/2/2017 Daniel J. Ryan 2nd Suffolk 2/1/2017 Sean Garballey 23rd Middlesex 2/2/2017 Joan B. Lovely Second Essex 2/2/2017 Daniel M. Donahue 16th Worcester 2/2/2017 Bud Williams 11th Hampden 2/2/2017 Jumes B. Matias 16th Essex 2/2/2017 Juna B. Matias 16th Essex 2/2/2017	David Paul Linsky	5th Middlesex	1/30/2017
Mark C. Montigny Second Bristol and Plymouth 1/30/2017 Sal N. DiDomenico Middlesex and Suffolk 1/30/2017 José F. Tosado 9th Hampden 1/31/2017 Patrick M. O'Connor Plymouth and Norfolk 1/31/2017 Kay Khan 11th Middlesex 1/31/2017 John F. Keenan Norfolk and Plymouth 1/31/2017 James B. Eldridge Middlesex and Worcester 1/31/2017 Julian Cyr Cape and Islands 2/1/2017 Junes M. Cantwell 4th Plymouth 2/1/2017 Junes M. Cantwell 4th Plymouth 2/1/2017 Steven Ultrino 33rd Middlesex 3rd Middlesex 2/1/2017 Kate Hogan 3rd Middlesex 3rd Middlesex 2/1/2017 Kenneth I. Gordon 21st Middlesex 2/1/2017 Mary S. Keefe 15th Worcester 2/2/2017 Daniel J. Ryan 2nd Suffolk 2/2/2017 Joan B. Lovely Second Essex 2/2/2017 Junes J. O'Day 14th Worcester 2/2/2017 Joan B. Matias 16th Essex 2/2/2017 Joan B. Matias 16th Essex 2/2/2017 Juna B. Matias	Kenneth J. Donnelly	Fourth Middlesex	1/30/2017
Sal N. DiDomenico Middlesex and Suffolk 1/30/2017 Patrick M. O'Connor Plymouth and Norfolk 1/31/2017 Kay Khan IIth Middlesex I/31/2017 John F. Keenan Norfolk and Plymouth I/31/2017 Paul R. Heroux 2nd Bristol Julian Cyr Cape and Islands Jennifer L. Flanagan Worcester and Middlesex V/1/2017 Johnes M. Cantwell Lori A. Ehrlich Steven Ultrino Steven Ultrino Sonia Chang-Diaz Kenneth I. Gordon Johned J. Syan Second Suffolk Vorcester Vandidlesex V/1/2017 Sean Garballey Variablesex Variablesex V/2/2017 Sean Garballey Variablesex Variable	Denise Provost	27th Middlesex	1/30/2017
José F. Tosado  9th Hampden  1/31/2017 Patrick M. O'Connor  Plymouth and Norfolk  1/31/2017 Kay Khan  Ith Middlesex  1/31/2017 John F. Keenan  Norfolk and Plymouth  1/31/2017 Paul R. Heroux  2nd Bristol  James B. Eldridge  Middlesex and Worcester  Julian Cyr  Cape and Islands  2/1/2017 James M. Cantwell  Ath Plymouth  2/1/2017 Lori A. Ehrlich  8th Essex  2/1/2017 Steven Ultrino  33rd Middlesex  2/1/2017 Sonia Chang-Diaz  Kenneth I. Gordon  21st Middlesex  2/1/2017 Mary S. Keefe  15th Worcester  2/2/2017 Sean Garballey  23rd Middlesex  2/2/2017 Joan B. Lovely  Second Essex  2/2/2017 James J. O'Day  14th Worcester  2/2/2017 Colleen M. Garry  Juana B. Matias  16th Essex  1/31/2017  Istandelsex  1/31/2017  1/3	Mark C. Montigny	Second Bristol and Plymouth	1/30/2017
José F. Tosado9th Hampden1/31/2017Patrick M. O'ConnorPlymouth and Norfolk1/31/2017Kay Khan11th Middlesex1/31/2017John F. KeenanNorfolk and Plymouth1/31/2017Paul R. Heroux2nd Bristol1/31/2017James B. EldridgeMiddlesex and Worcester1/31/2017Julian CyrCape and Islands2/1/2017Jennifer L. FlanaganWorcester and Middlesex2/1/2017James M. Cantwell4th Plymouth2/1/2017Lori A. Ehrlich8th Essex2/1/2017Kate Hogan3rd Middlesex2/1/2017Kate Hogan3rd Middlesex2/1/2017Sonia Chang-DiazSecond Suffolk2/1/2017Kenneth I. Gordon21st Middlesex2/1/2017Mary S. Keefe15th Worcester2/2/2017Daniel J. Ryan2nd Suffolk2/2/2017Sean Garballey23rd Middlesex2/2/2017Joan B. LovelySecond Essex2/2/2017Daniel M. Donahue16th Worcester2/2/2017James J. O'Day14th Worcester2/2/2017Colleen M. Garry36th Middlesex2/2/2017Juana B. Matias16th Essex2/2/2017	Sal N. DiDomenico	Middlesex and Suffolk	1/30/2017
Kay Khan  IIth Middlesex  Norfolk and Plymouth  I/31/2017  Paul R. Heroux  Indian Cyr  Jennifer L. Flanagan  Worcester and Middlesex  Z/1/2017  James M. Cantwell  Lori A. Ehrlich  Steven Ultrino  Sonia Chang-Diaz  Kenneth I. Gordon  Z1st Middlesex  Z1/2017  Jamery S. Keefe  I5th Worcester  Z2/2017  Joan B. Lovely  Daniel M. Donahue  Ioth Worcester  Joan B. Matias  Ith Middlesex  I/31/2017  I/3	José F. Tosado		1/31/2017
Kay Khan11th Middlesex1/31/2017John F. KeenanNorfolk and Plymouth1/31/2017Paul R. Heroux2nd Bristol1/31/2017James B. EldridgeMiddlesex and Worcester1/31/2017Julian CyrCape and Islands2/1/2017Jennifer L. FlanaganWorcester and Middlesex2/1/2017James M. Cantwell4th Plymouth2/1/2017Lori A. Ehrlich8th Essex2/1/2017Steven Ultrino33rd Middlesex2/1/2017Kate Hogan3rd Middlesex2/1/2017Sonia Chang-DiazSecond Suffolk2/1/2017Kenneth I. Gordon21st Middlesex2/1/2017Mary S. Keefe15th Worcester2/2/2017Daniel J. Ryan2nd Suffolk2/2/2017Sean Garballey23rd Middlesex2/2/2017Joan B. LovelySecond Essex2/2/2017Daniel M. Donahue16th Worcester2/2/2017Bud Williams11th Hampden2/2/2017James J. O'Day14th Worcester2/2/2017Colleen M. Garry36th Middlesex2/2/2017Juana B. Matias16th Essex2/2/2017	Patrick M. O'Connor	Plymouth and Norfolk	1/31/2017
Paul R. Heroux  2nd Bristol  Middlesex and Worcester  1/31/2017  Julian Cyr  Cape and Islands  2/1/2017  Junes M. Cantwell  Lori A. Ehrlich  Steven Ultrino  33rd Middlesex  2/1/2017  Kate Hogan  3rd Middlesex  2/1/2017  Second Suffolk  2/1/2017  Mary S. Keefe  15th Worcester  2nd Suffolk  2/2/2017  Sean Garballey  Janes M. Contwel  16th Worcester  2/2/2017  Bud Williams  11th Hampden  1/31/2017  1/31/201	Kay Khan	11th Middlesex	1/31/2017
James B. EldridgeMiddlesex and Worcester1/31/2017Julian CyrCape and Islands2/1/2017Jennifer L. FlanaganWorcester and Middlesex2/1/2017James M. Cantwell4th Plymouth2/1/2017Lori A. Ehrlich8th Essex2/1/2017Steven Ultrino33rd Middlesex2/1/2017Kate Hogan3rd Middlesex2/1/2017Sonia Chang-DiazSecond Suffolk2/1/2017Kenneth I. Gordon21st Middlesex2/1/2017Mary S. Keefe15th Worcester2/2/2017Daniel J. Ryan2nd Suffolk2/2/2017Sean Garballey23rd Middlesex2/2/2017Joan B. LovelySecond Essex2/2/2017Daniel M. Donahue16th Worcester2/2/2017Bud Williams11th Hampden2/2/2017James J. O'Day14th Worcester2/2/2017Colleen M. Garry36th Middlesex2/2/2017Juana B. Matias16th Essex2/2/2017	John F. Keenan	Norfolk and Plymouth	1/31/2017
Julian Cyr Jennifer L. Flanagan Worcester and Middlesex 2/1/2017 James M. Cantwell Lori A. Ehrlich Steven Ultrino 33rd Middlesex 2/1/2017 Kate Hogan 3rd Middlesex 2/1/2017 Sonia Chang-Diaz Kenneth I. Gordon Mary S. Keefe 15th Worcester Daniel J. Ryan 2nd Suffolk 2/2/2017 Sean Garballey Joan B. Lovely Daniel M. Donahue 16th Worcester 2/2/2017 James J. O'Day Colleen M. Garry Juana B. Matias 2/1/2017 James J. Other and Islands 2/1/2017 2/1/2017 2/1/2017 2/1/2017 2/1/2017 2/201	Paul R. Heroux	2nd Bristol	1/31/2017
Jennifer L. FlanaganWorcester and Middlesex2/1/2017James M. Cantwell4th Plymouth2/1/2017Lori A. Ehrlich8th Essex2/1/2017Steven Ultrino33rd Middlesex2/1/2017Kate Hogan3rd Middlesex2/1/2017Sonia Chang-DiazSecond Suffolk2/1/2017Kenneth I. Gordon21st Middlesex2/1/2017Mary S. Keefe15th Worcester2/2/2017Daniel J. Ryan2nd Suffolk2/2/2017Sean Garballey23rd Middlesex2/2/2017Joan B. LovelySecond Essex2/2/2017Daniel M. Donahue16th Worcester2/2/2017Bud Williams11th Hampden2/2/2017James J. O'Day14th Worcester2/2/2017Colleen M. Garry36th Middlesex2/2/2017Juana B. Matias16th Essex2/2/2017	James B. Eldridge	Middlesex and Worcester	1/31/2017
James M. Cantwell4th Plymouth2/1/2017Lori A. Ehrlich8th Essex2/1/2017Steven Ultrino33rd Middlesex2/1/2017Kate Hogan3rd Middlesex2/1/2017Sonia Chang-DiazSecond Suffolk2/1/2017Kenneth I. Gordon21st Middlesex2/1/2017Mary S. Keefe15th Worcester2/2/2017Daniel J. Ryan2nd Suffolk2/2/2017Sean Garballey23rd Middlesex2/2/2017Joan B. LovelySecond Essex2/2/2017Daniel M. Donahue16th Worcester2/2/2017Jud Williams11th Hampden2/2/2017James J. O'Day14th Worcester2/2/2017Colleen M. Garry36th Middlesex2/2/2017Juana B. Matias16th Essex2/2/2017	Julian Cyr	Cape and Islands	2/1/2017
Lori A. Ehrlich Steven Ultrino 33rd Middlesex 2/1/2017 Kate Hogan 3rd Middlesex 2/1/2017 Sonia Chang-Diaz Second Suffolk 2/1/2017 Kenneth I. Gordon 21st Middlesex 2/1/2017 Mary S. Keefe 15th Worcester 2/2/2017 Daniel J. Ryan 2nd Suffolk 2/2/2017 Sean Garballey 23rd Middlesex 2/2/2017 Joan B. Lovely Second Essex 2/2/2017 Daniel M. Donahue 16th Worcester 2/2/2017 James J. O'Day 14th Worcester 2/2/2017 Colleen M. Garry Juana B. Matias 16th Essex 2/2/2017	Jennifer L. Flanagan	Worcester and Middlesex	2/1/2017
Steven Ultrino  Steven Ultrino  Sard Middlesex  2/1/2017  Sonia Chang-Diaz  Second Suffolk  2/1/2017  Kenneth I. Gordon  Mary S. Keefe  15th Worcester  2/2/2017  Daniel J. Ryan  Sean Garballey  23rd Middlesex  2/2/2017  Joan B. Lovely  Second Essex  2/2/2017  Bud Williams  11th Hampden  2/2/2017  James J. O'Day  Colleen M. Garry  Juana B. Matias  2/1/2017  33rd Middlesex  2/1/2017  2/2/2017  2/2/2017  2/2/2017  2/2/2017  2/2/2017  2/2/2017  2/2/2017  2/2/2017	James M. Cantwell	4th Plymouth	2/1/2017
Kate Hogan3rd Middlesex2/1/2017Sonia Chang-DiazSecond Suffolk2/1/2017Kenneth I. Gordon21st Middlesex2/1/2017Mary S. Keefe15th Worcester2/2/2017Daniel J. Ryan2nd Suffolk2/2/2017Sean Garballey23rd Middlesex2/2/2017Joan B. LovelySecond Essex2/2/2017Daniel M. Donahue16th Worcester2/2/2017Bud Williams11th Hampden2/2/2017James J. O'Day14th Worcester2/2/2017Colleen M. Garry36th Middlesex2/2/2017Juana B. Matias16th Essex2/2/2017	Lori A. Ehrlich	8th Essex	2/1/2017
Sonia Chang-Diaz Second Suffolk Zenneth I. Gordon Zent Middlesex Zent Middlesex Zent Middlesex Zent Mary S. Keefe Zent Suffolk Zent Suffolk Zent Suffolk Zent Suffolk Zent Suffolk Zent Suffolk Zent Middlesex Zent Middlesex Zent Middlesex Zent Suffolk Zent Sean Garballey Zent Middlesex Zent Suffolk Zent S	Steven Ultrino	33rd Middlesex	2/1/2017
Kenneth I. Gordon       21st Middlesex       2/1/2017         Mary S. Keefe       15th Worcester       2/2/2017         Daniel J. Ryan       2nd Suffolk       2/2/2017         Sean Garballey       23rd Middlesex       2/2/2017         Joan B. Lovely       Second Essex       2/2/2017         Daniel M. Donahue       16th Worcester       2/2/2017         Bud Williams       11th Hampden       2/2/2017         James J. O'Day       14th Worcester       2/2/2017         Colleen M. Garry       36th Middlesex       2/2/2017         Juana B. Matias       16th Essex       2/2/2017	Kate Hogan	3rd Middlesex	2/1/2017
Mary S. Keefe 15th Worcester 2/2/2017 Daniel J. Ryan 2nd Suffolk 2/2/2017 Sean Garballey 23rd Middlesex 2/2/2017 Joan B. Lovely Second Essex 2/2/2017 Daniel M. Donahue 16th Worcester 2/2/2017 Bud Williams 11th Hampden 2/2/2017 James J. O'Day 14th Worcester 2/2/2017 Colleen M. Garry 36th Middlesex 2/2/2017 Juana B. Matias 16th Essex 2/2/2017	Sonia Chang-Diaz	Second Suffolk	2/1/2017
Daniel J. Ryan       2nd Suffolk       2/2/2017         Sean Garballey       23rd Middlesex       2/2/2017         Joan B. Lovely       Second Essex       2/2/2017         Daniel M. Donahue       16th Worcester       2/2/2017         Bud Williams       11th Hampden       2/2/2017         James J. O'Day       14th Worcester       2/2/2017         Colleen M. Garry       36th Middlesex       2/2/2017         Juana B. Matias       16th Essex       2/2/2017	Kenneth I. Gordon	21st Middlesex	2/1/2017
Sean Garballey  23rd Middlesex  2/2/2017  Joan B. Lovely  Second Essex  2/2/2017  Daniel M. Donahue  16th Worcester  2/2/2017  Bud Williams  11th Hampden  2/2/2017  James J. O'Day  14th Worcester  2/2/2017  Colleen M. Garry  36th Middlesex  2/2/2017  Juana B. Matias  16th Essex	Mary S. Keefe	15th Worcester	2/2/2017
Joan B. Lovely       Second Essex       2/2/2017         Daniel M. Donahue       16th Worcester       2/2/2017         Bud Williams       11th Hampden       2/2/2017         James J. O'Day       14th Worcester       2/2/2017         Colleen M. Garry       36th Middlesex       2/2/2017         Juana B. Matias       16th Essex       2/2/2017	Daniel J. Ryan	2nd Suffolk	2/2/2017
Daniel M. Donahue       16th Worcester       2/2/2017         Bud Williams       11th Hampden       2/2/2017         James J. O'Day       14th Worcester       2/2/2017         Colleen M. Garry       36th Middlesex       2/2/2017         Juana B. Matias       16th Essex       2/2/2017	Sean Garballey	23rd Middlesex	2/2/2017
Bud Williams 11th Hampden 2/2/2017  James J. O'Day 14th Worcester 2/2/2017  Colleen M. Garry 36th Middlesex 2/2/2017  Juana B. Matias 16th Essex 2/2/2017	Joan B. Lovely	Second Essex	2/2/2017
James J. O'Day14th Worcester2/2/2017Colleen M. Garry36th Middlesex2/2/2017Juana B. Matias16th Essex2/2/2017	Daniel M. Donahue	16th Worcester	2/2/2017
Colleen M. Garry 36th Middlesex 2/2/2017 Juana B. Matias 16th Essex 2/2/2017	Bud Williams	11th Hampden	2/2/2017
Juana B. Matias 16th Essex 2/2/2017	James J. O'Day	14th Worcester	2/2/2017
	Colleen M. Garry	36th Middlesex	2/2/2017
Adam G. Hinds Berkshire, Hampshire, Franklin and 2/2/2017	Juana B. Matias	16th Essex	2/2/2017
	Adam G. Hinds	Berkshire, Hampshire, Franklin and	2/2/2017

	Hampden	
James E. Timilty	Bristol and Norfolk	2/3/2017
Kathleen O'Connor Ives	First Essex	2/3/2017
Eileen M. Donoghue	First Middlesex	2/3/2017
Thomas M. Stanley	9th Middlesex	2/3/2017
Daniel Cullinane	12th Suffolk	2/3/2017
Carole A. Fiola	6th Bristol	2/3/2017
Michael O. Moore	Second Worcester	2/3/2017
Elizabeth A. Malia	11th Suffolk	2/3/2017
Harold P. Naughton, Jr.	12th Worcester	2/3/2017
Eric P. Lesser	First Hampden and Hampshire	2/3/2017
Walter F. Timilty	Norfolk, Bristol and Plymouth	2/3/2017
Linda Dorcena Forry	First Suffolk	2/3/2017
Chris Walsh	6th Middlesex	2/3/2017
Carmine L. Gentile	13th Middlesex	2/6/2017
Bradford R. Hill	4th Essex	3/10/2017
James Arciero	2nd Middlesex	5/11/2017
Dylan Fernandes	Barnstable, Dukes and Nantucket	6/20/2017
Cindy F. Friedman	Fourth Middlesex	8/14/2017

## **SENATE . . . . . . . . . . . . . . . No. 499**

By Ms. Chandler, a petition (accompanied by bill, Senate, No. 499) of Harriette L. Chandler, Robert M. Koczera, Jennifer E. Benson, Sarah K. Peake and other members of the General Court for legislation relative to women's health and economic equity. Financial Services.

# [SIMILAR MATTER FILED IN PREVIOUS SESSION SEE SENATE, NO. 483 OF 2015-2016.]

### The Commonwealth of Alassachusetts

In the One Hundred and Ninetieth General Court (2017-2018)

An Act advancing contraceptive coverage and economic security in our state (ACCESS).

Be it enacted by the Senate and House of Representatives in General Court assembled, and by the authority of the same, as follows:

- SECTION 1. Chapter 32A of the General Laws, as appearing in the 2014 Official
- 2 Edition, is hereby amended by inserting after section 27 the following section:
- 3 Section 28. (a) Any coverage offered by the commission to any active or retired
- 4 employee of the commonwealth insured under the group insurance commission shall provide
- 5 coverage for:
- 6 (1) all Food and Drug Administration ("FDA")-approved contraceptive drugs, devices
- 7 and other products. This includes all FDA-approved contraceptive drugs, devices, and products,
- 8 as prescribed by the enrollee's provider or otherwise authorized under state or federal law. The
- 9 following apply:

- (i) If there is a therapeutic equivalent of an FDA-approved contraceptive drug, device, or product, the Commission shall provide coverage for either the original FDA-approved contraceptive drug, device, or product or at least one of its therapeutic equivalents; and
  - (ii) If the covered contraceptive drug, device, or product is deemed medically inadvisable by the covered person's provider, the Commission shall defer to the determination and judgment of the attending provider and provide coverage for an alternate prescribed contraceptive drug, device, or product;
- (2) all FDA-approved contraceptive drugs available over the counter without a prescription;
- (3) a single dispensing to an enrollee of a supply of prescription contraceptives for a 12-month period;
  - (4) voluntary sterilization procedures;

- (5) patient education and counseling on contraception; and
- (6) follow-up services related to the drugs, devices, products and procedures covered under this subsection, including, but not limited to, management of side effects, counseling for continued adherence, and device insertion and removal.
- (b) (1) Coverage provided under this subsection shall not be subject to any deductible, coinsurance, copayment or any other cost-sharing requirement. Any coverage offered by the commission shall not impose any restrictions or delays in the coverage, including medical management techniques such as denials, step therapy, or prior authorization.

30 (2) Benefits for an enrollee under this section shall also be provided for such enrollee's31 covered spouse and covered dependents.

- (3) Nothing in this section shall be construed to exclude coverage for contraceptive drugs, devices, products and procedures as prescribed by a provider, acting within the his/her scope of practice, for reasons other than contraceptive purposes, such as for decreasing the risk of ovarian cancer or eliminating symptoms of menopause or for contraception that is necessary to preserve the life or health of such enrollee, or such enrollee's covered spouse, and/or covered dependents.
- (4) Nothing in this section shall be construed to deny or restrict in any way the group insurance commission's authority to ensure plan compliance with this chapter.
- (5) Nothing in this section shall be construed to require the commission to cover experimental or investigational treatments.
- (c) For purposes of this section, the following definitions shall apply, unless the context clearly requires otherwise:
- "Provider", an individual or facility licensed, certified, or otherwise authorized or permitted by law to administer health care in the ordinary course of business or professional practice.
- Contraceptive drugs, devices, or products classified as "therapeutic equivalents" means (1) they are approved as safe and effective; and (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; provided further that to be considered a "therapeutic equivalent", the

- contraceptive drugs, devices, or products must be assigned the same therapeutic equivalence code by the FDA.
- SECTION 2. Chapter 118E of the General Laws, as so appearing, is hereby amended by inserting after section 10I the following section:

- 10J (a) The division and its contracted health insurers, health plans, health maintenance organizations, behavioral health management firms and third-party administrators under contract to a Medicaid managed care organization or primary care clinician plan shall provide coverage for:
- (1) all FDA-approved contraceptive drugs, devices and other products. This includes all FDA-approved contraceptive drugs, devices, and products, as prescribed by an enrollee's provider or otherwise authorized under state or federal law. The following apply:
- (i) If there is a therapeutic equivalent of an FDA-approved contraceptive drug, device, or product, the division shall provide coverage for either the original FDA-approved contraceptive drug, device, or product or at least one of its therapeutic equivalents; and
- (ii) If the covered contraceptive drug, device, or product is deemed medically inadvisable by the covered person's provider, the division shall defer to the determination and judgment of the attending provider and provide coverage for an alternate prescribed contraceptive drug, device, or product;
- 69 (2) all FDA-approved contraceptive drugs available over the counter without a 70 prescription;

- 71 (3) a single dispensing to a beneficiary of a supply of prescription contraceptives for a 72 12-month period;
  - (4) voluntary sterilization procedures;

73

78

79

80

81

82

83

84

85

86

87

88

89

90

- 74 (5) patient education and counseling on contraception; and
- 75 (6) follow-up services related to the drugs, devices, products and procedures covered 76 under this subsection, including, but not limited to, management of side effects, counseling for 77 continued adherence, and device insertion and removal.
  - (b) (1) The division shall not impose a deductible, coinsurance, copayment or any other cost-sharing requirement on the coverage provided pursuant to this subsection. Cost sharing shall not be imposed on any person with coverage under this chapter.

The division shall not impose any restrictions or delays on the coverage required under this section, including medical management techniques such as denials, step therapy, or prior authorization.

- (2) Benefits for an enrollee under this section shall be the same for such enrollee's covered spouse and covered dependents.
- (3) Nothing in this section shall be construed to exclude coverage for contraceptive drugs, devices, products and procedures as prescribed by a provider, acting within his/her scope of practice, for reasons other than contraceptive purposes, such as decreasing the risk of ovarian cancer or eliminating symptoms of menopause or for contraception that is necessary to preserve the life or health of such enrollee, or such enrollee's covered spouse and/or covered dependents.

(4) Nothing in this section shall be construed to deny or restrict in any way the division of medical assistance's authority to ensure its contracted health insurers, health plans, health maintenance organizations, behavioral health management firms and third-party administrators under contract to a Medicaid managed care organization or primary care clinician plan are in compliance with this chapter.

- (5) Nothing in this section shall be construed to require the division to cover experimental or investigational treatments.
- (c) For purposes of this section, the following definitions shall apply, unless the context clearly requires otherwise:

"Provider", an individual or facility licensed, certified, or otherwise authorized or permitted by law to administer health care in the ordinary course of business or professional practice.

Contraceptive drugs, devices, or products classified as "therapeutic equivalents" means (1) they are approved as safe and effective; and (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; provided further that to be considered a "therapeutic equivalent", the contraceptive drugs, devices, or products must be assigned the same therapeutic equivalence code by the FDA.

SECTION 3. Chapter 175 of the General Laws, as so appearing, is hereby amended by inserting after section 47W(c) the following:

(d) An individual policy of accident and sickness insurance issued pursuant to section 108 that provides hospital expense and surgical expense and any group blanket policy of accident and sickness insurance issued pursuant to section 110 that provides hospital expense and surgical expense insurance, delivered, issued or renewed by agreement between the insurer and the policyholder, within or without the Commonwealth, (hereinafter "policy") shall provide benefits for residents of the Commonwealth and all group members having a principal place of employment within the Commonwealth coverage for all of the following services and contraceptive methods:

- (1) all FDA-approved contraceptive drugs, devices and other products. This includes all FDA-approved contraceptive drugs, devices, and products, as prescribed by the enrollee's provider or otherwise authorized under state or federal law. The following apply:
- (i) If there is a therapeutic equivalent of an FDA-approved contraceptive drug, device, or product, a policy shall provide coverage for either the original FDA-approved contraceptive drug, device, or product or at least one of its therapeutic equivalents; and
- (ii) If the covered contraceptive drug, device, or product is deemed medically inadvisable by the covered person's provider, a policy shall defer to the determination and judgment of the attending provider and provide coverage for an alternate prescribed contraceptive drug, device, or product;
- (2) all FDA-approved contraceptive drugs available over the counter without aprescription;
- (3) a single dispensing to a beneficiary of a supply of prescription contraceptives for a
   12-month period;

(4) voluntary sterilization procedures;

- (5) patient education and counseling on contraception; and
- (6) follow-up services related to the drugs, devices, products and procedures covered under this section, including, but not limited to, management of side effects, counseling for continued adherence, and device insertion and removal.
- (e) (1) A policy subject to this section shall not impose a deductible, coinsurance, copayment or any other cost-sharing requirement on the coverage provided pursuant to this section. Except as otherwise authorized under this section, a policy shall not impose any restrictions or delays on the coverage required under this section, including medical management techniques such as denials, step therapy, or prior authorization.
- (2) Benefits for an enrollee shall be the same for such enrollee's covered spouse and covered dependents.
- (f)(1) This section shall not apply to a policy if such policy is purchased by an employer that is a church or qualified church-controlled organization.
- (2) A church or qualified church-controlled organization that invokes the exemption provided under subsection (f)(1) shall provide written notice to prospective enrollees prior to enrollment with the plan, listing the contraceptive health care methods and services such employer refuses to cover for religious reasons.
- (g) Nothing in this section shall be construed to exclude coverage for contraceptive drugs, devices, products and procedures as prescribed by a provider, acting within his/her scope of practice, for reasons other than contraceptive purposes, such as decreasing the risk of ovarian

cancer or eliminating symptoms of menopause or for contraception that is necessary to preserve the life or health of an enrollee.

- (h) Nothing in this section shall be construed to deny or restrict in any way the division of insurance's authority to ensure compliance with this chapter.
- (i) Nothing in this section shall be construed to require an individual or group policy of accident or sickness to cover experimental or investigational treatments.
- (j) For purposes of this section, the following definitions shall apply, unless the context clearly requires otherwise:
- "Church", a church, a convention or association of churches, or an elementary or secondary school which is controlled, operated, or principally supported by a church or by a convention or association of churches.
- "Provider", an individual or facility licensed, certified, or otherwise authorized or permitted by law to administer health care in the ordinary course of business or professional practice.
- "Qualified church-controlled organization", described in section 501(c)(3) of the Internal Revenue Code, other than an organization which--
- (i) offers goods, services, or facilities for sale, other than on an incidental basis, to the general public, other than goods, services, or facilities which are sold at a nominal charge which is substantially less than the cost of providing such goods, services, or facilities; and

(ii) normally receives more than 25 percent of its support from either (I) governmental sources, or (II) receipts from admissions, sales of merchandise, performance of services, or furnishing of facilities, in activities which are not unrelated trades or businesses, or both.

Contraceptive drugs, devices, or products classified as "therapeutic equivalents" means (1) they are approved as safe and effective; and (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; provided further that to be considered a "therapeutic equivalent", the contraceptive drugs, devices, or products must be assigned the same therapeutic equivalence code by the FDA.

SECTION 4. Chapter 176A of the General Laws, as so appearing, is hereby amended by inserting after section 8W(c) the following:

- (d) Any contract between a subscriber and the corporation under an individual or group hospital service plan that is delivered, issued or renewed within or without the Commonwealth and that provides benefits for outpatient services shall provide to all individual subscribers and members within the Commonwealth and to all group members having a principal place of employment within the Commonwealth coverage for all of the following services and contraceptive methods:
- (1) all FDA-approved contraceptive drugs, devices and other products. This includes all FDA-approved contraceptive drugs, devices, and products, as prescribed by the enrollee's provider or otherwise authorized under state or federal law. The following apply:

- (i) If there is a therapeutic equivalent of an FDA-approved contraceptive drug, device, or product, an individual or group hospital service plan shall provide coverage for either the original FDA-approved contraceptive drug, device, or product or at least one of its therapeutic equivalents; and
- (ii) If the covered contraceptive drug, device, or product is deemed medically inadvisable by the covered person's provider, an individual or group hospital service plan shall defer to the determination and judgment of the attending provider and provide coverage for an alternate prescribed contraceptive drug, device, or product;
- (2) all FDA-approved contraceptive drugs available over the counter without a prescription;
- (3) a single dispensing to a beneficiary of a supply of prescription contraceptives for a 12-month period;
  - (4) voluntary sterilization procedures;

- (5) patient education and counseling on contraception; and
- (6) follow-up services related to the drugs, devices, products and procedures covered under this subsection, including, but not limited to, management of side effects, counseling for continued adherence, and device insertion and removal.
- (e) (1) A contract subject to this section shall not impose a deductible, coinsurance, copayment or any cost-sharing requirement on the coverage. Except as otherwise authorized under this section, a contract shall not impose any restrictions or delays on the coverage required

under this section, including medical management techniques such as denials, step therapy, or prior authorization.

- (2) Benefits for an enrollee under this subsection shall be the same for an enrollee's covered spouse and covered dependents.
- (f) (1) The requirements of subsection (d) shall not apply to a contract between a subscriber and a corporation under an individual or group hospital service plan that is delivered, issued, or renewed within or without the Commonwealth that is purchased by an employer that is a church or qualified church-controlled organization.
- (2) A church or qualified church-controlled organization that invokes the exemption provided under subsection (f)(1) shall provide written notice to prospective enrollees prior to enrollment with the plan, listing the contraceptive health care methods and services such employer refuses to cover for religious reasons.
- (g) Nothing in this subsection shall be construed to exclude coverage for contraceptive drugs, devices, products and procedures as prescribed by a provider, acting within his/her scope of practice, for reasons other than contraceptive purposes, such as decreasing the risk of ovarian cancer or eliminating symptoms of menopause or for contraception that is necessary to preserve the life or health of an enrollee.
- (h) Nothing in this subsection shall be construed to deny or restrict in any way the division of insurance's authority to ensure contract compliance with this chapter.
- (i) Nothing in this section shall be construed to require a contract to cover experimental or investigational treatments.

236 (j) For purposes of this section, the following definitions shall apply, unless the context 237 clearly requires otherwise:

"Church", a church, a convention or association of churches, or an elementary or secondary school which is controlled, operated, or principally supported by a church or by a convention or association of churches.

"Provider", an individual or facility licensed, certified, or otherwise authorized or permitted by law to administer health care in the ordinary course of business or professional practice.

"Qualified church-controlled organization", described in section 501(c)(3) of the Internal Revenue Code, other than an organization which--

- (i) offers goods, services, or facilities for sale, other than on an incidental basis, to the general public, other than goods, services, or facilities which are sold at a nominal charge which is substantially less than the cost of providing such goods, services, or facilities; and
- (ii) normally receives more than 25 percent of its support from either (I) governmental sources, or (II) receipts from admissions, sales of merchandise, performance of services, or furnishing of facilities, in activities which are not unrelated trades or businesses, or both.

Contraceptive drugs, devices, or products classified as "therapeutic equivalents" means (1) they are approved as safe and effective; and (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; provided further that to be considered a "therapeutic equivalent", the

contraceptive drugs, devices, or products must be assigned the same therapeutic equivalence code by the FDA.

- SECTION 5. Chapter 176B of the General Laws, as so appearing, is hereby amended by inserting after section 4W(c) the following:
- (d) Any subscription certificate under an individual or group medical service agreement that is delivered, issued or renewed within or without the Commonwealth and that provides benefits for outpatient services shall provide to all individual subscribers and members within the Commonwealth and to all group members having a principal place of employment within the Commonwealth coverage for all of the following services and contraceptive methods:
- (1) all FDA-approved contraceptive drugs, devices and other products. This includes all FDA-approved contraceptive drugs, devices, and products, as prescribed by the enrollee's provider or otherwise authorized under state or federal law. The following apply:
- (i) If there is a therapeutic equivalent of an FDA-approved contraceptive drug, device, or product, an individual or group medical service agreement shall provide for coverage for either the original FDA-approved contraceptive drug, device, or product or at least one of its therapeutic equivalents; and
- (ii) If the covered contraceptive drug, device, or product is deemed medically inadvisable by the covered person's provider, an individual or group medical service agreement shall defer to the determination and judgment of the attending provider and provide coverage for an alternate prescribed contraceptive drug, device, or product;

277 (2) all FDA-approved contraceptive drugs available over the counter without a 278 prescription; 279 (3) a single dispensing to a beneficiary of a supply of prescription contraceptives for a 280 12-month period; 281 (4) voluntary sterilization procedures; 282 (5) patient education and counseling on contraception; and 283 (6) follow-up services related to the drugs, devices, products and procedures covered 284 under this subsection, including, but not limited to, management of side effects, counseling for 285 continued adherence, and device insertion and removal. 286 (e) (1) A medical service agreement subject to this section shall not impose a deductible, 287 coinsurance, copayment or any other cost-sharing requirement on the coverage provided. Except 288 as otherwise authorized under this section, a medical service agreement shall not impose any 289 restrictions or delays on the coverage required under this section, including medical management 290 techniques such as denials, step therapy, or prior authorization. 291 (2) Benefits for an enrollee under this subsection shall be the same for such enrollee's 292 covered spouse and covered dependents. 293 (f) (1) The requirements of this subsection shall not apply to a medical service agreement 294 that is delivered, issued, or renewed within or without the Commonwealth that is purchased by 295 an employer that is a church or qualified church-controlled organization.

provided under subsection (f)(1) shall provide written notice to prospective enrollees prior to

(2) A church or qualified church-controlled organization that invokes the exemption

296

enrollment with the plan, listing the contraceptive health care methods and services the employer refuses to cover for religious reasons.

- (g) Nothing in this subsection shall be construed to exclude coverage for contraceptive drugs, devices, products and procedures as prescribed by a provider, acting within his/her scope of practice, for reasons other than contraceptive purposes, such as decreasing the risk of ovarian cancer or eliminating symptoms of menopause or for contraception that is necessary to preserve the life or health of an enrollee.
- (h) Nothing in this subsection shall be construed to deny or restrict in any way the division of insurance's authority to ensure medical service agreement compliance with this chapter.
- (i) Nothing in this subsection shall be construed to require an individual or group medical service agreement to cover experimental or investigational treatments.
- (j) For purposes of this section, the following definitions shall apply, unless the context clearly requires otherwise:
- "Church", a church, a convention or association of churches, or an elementary or secondary school which is controlled, operated, or principally supported by a church or by a convention or association of churches.
- "Provider", an individual or facility licensed, certified, or otherwise authorized or permitted by law to administer health care in the ordinary course of business or professional practice.

"Qualified church-controlled organization", described in section 501(c)(3) of the Internal Revenue Code, other than an organization which--

- (i) offers goods, services, or facilities for sale, other than on an incidental basis, to the general public, other than goods, services, or facilities which are sold at a nominal charge which is substantially less than the cost of providing such goods, services, or facilities; and
- (ii) normally receives more than 25 percent of its support from either (I) governmental sources, or (II) receipts from admissions, sales of merchandise, performance of services, or furnishing of facilities, in activities which are not unrelated trades or businesses, or both.

Contraceptive drugs, devices, or products classified as "therapeutic equivalents" means (1) they are approved as safe and effective; and (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; provided further that to be considered a "therapeutic equivalent", the contraceptive drugs, devices, or products must be assigned the same therapeutic equivalence code by the FDA.

- SECTION 6. Chapter 176G of the General Laws, as so appearing, is hereby amended by inserting after section 4O(c) the following:
- (d) Any individual or group health maintenance contract that is issued, renewed or delivered within or without the Commonwealth and that provides benefits for outpatient prescription drugs or devices shall provide to residents of the Commonwealth and to persons having a principal place of employment within the Commonwealth coverage for all of the following services and contraceptive methods:

340	(1) all FDA-approved contraceptive drugs, devices and other products. This includes all
841	FDA-approved contraceptive drugs, devices, and products, as prescribed by the enrollee's
342	provider or otherwise authorized under state or federal law. The following apply:
343	(i) If there is a therapeutic equivalent of an FDA-approved contraceptive drug, device, or
344	product, a health maintenance contract shall provide coverage for either the original FDA-
345	approved contraceptive drug, device, or product or at least one of its therapeutic equivalents; and
346	(ii) If the covered contraceptive drug, device, or product is deemed medically inadvisable
347	by the covered person's provider, a health maintenance contract shall defer to the determination
348	and judgment of the attending provider and provide coverage for an alternate prescribed
349	contraceptive drug, device, or product;
350	(2) all FDA-approved contraceptive drugs available over the counter without a
351	prescription;
352	(3) a single dispensing to a beneficiary of a supply of prescription contraceptives for a
353	12-month period;
354	(4) voluntary sterilization procedures;
355	(5) patient education and counseling on contraception; and
356	(6) follow-up services related to the drugs, devices, products and procedures covered
357	under this section, including, but not limited to, management of side effects, counseling for
358	continued adherence, and device insertion and removal.
359	(e) (1) A health maintenance contract shall not impose a deductible, coinsurance,

copayment or any other cost-sharing requirement on the coverage provided. Cost sharing shall

not be imposed on any MassHealth beneficiary. Except as otherwise authorized under this section, a health maintenance contract shall not impose any restrictions or delays on the coverage required under this section, including medical management techniques such as denials, step therapy, or prior authorization.

- (2) Benefits for an enrollee under this section shall be the same for such enrollee's covered spouse and covered dependents.
- (f) (1) The requirements of this subsection shall not apply to a health maintenance contract if that policy is purchased by an employer that is a church or qualified church-controlled organization.
- (2) A church or qualified church-controlled organization that invokes the exemption provided under subsection (f)(1) shall provide written notice to prospective enrollees prior to enrollment with the plan, listing the contraceptive health care services the employer refuses to cover for religious reasons.
- (g) Nothing in this subsection shall be construed to exclude coverage for contraceptive drugs, devices, products and procedures as prescribed by a provider, acting within his/her scope of practice, for reasons other than contraceptive purposes, such as decreasing the risk of ovarian cancer or eliminating symptoms of menopause or for contraception that is necessary to preserve the life or health of an enrollee.
- (h) Nothing in this subsection shall be construed to deny or restrict in any way the division of insurance's authority to ensure health maintenance contract compliance with this chapter.

(i) Nothing in this subsection shall be construed to require an individual or group healthmaintenance contract to cover experimental or investigational treatments.

(j) For purposes of this section, the following words shall have the following meanings, unless the context clearly requires otherwise:

"Church", a church, a convention or association of churches, or an elementary or secondary school which is controlled, operated, or principally supported by a church or by a convention or association of churches.

"Provider", an individual or facility licensed, certified, or otherwise authorized or permitted by law to administer health care in the ordinary course of business or professional practice.

"Qualified church-controlled organization", described in section 501(c)(3) of the Internal Revenue Code, other than an organization which--

- (i) offers goods, services, or facilities for sale, other than on an incidental basis, to the general public, other than goods, services, or facilities which are sold at a nominal charge which is substantially less than the cost of providing such goods, services, or facilities; and
- (ii) normally receives more than 25 percent of its support from either (I) governmental sources, or (II) receipts from admissions, sales of merchandise, performance of services, or furnishing of facilities, in activities which are not unrelated trades or businesses, or both.

Contraceptive drugs, devices, or products classified as "therapeutic equivalents" means (1) they are approved as safe and effective; and (2) they are pharmaceutical equivalents in that they (a) contain identical amounts of the same active drug ingredient in the same dosage form

and route of administration, and (b) meet compendial or other applicable standards of strength, quality, purity, and identity; provided further that to be considered a "therapeutic equivalent", the contraceptive drugs, devices, or products must be assigned the same therapeutic equivalence code by the FDA.

SECTION 7. Sections 1 through 6 of this act shall apply to all policies, contracts and certificates of health insurance subject to chapters 32A, chapter 118E, chapter 175, chapter 176A, chapter 176B, and chapter 176G which are delivered, issued or renewed on or after September 1, 2017.